Gopal Kumar Patidar

Dr. Gopal Kumar Patidar

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in Vox Sanguinis
Verified
Journal Article
Open access
PDF file
RGRuchika Goel
Ruchika Goel
EBEvan M. Bloch
Evan M. Bloch
FPFrance Pirenne
France Pirenne
AAArwa Z. Al‐Riyami
Arwa Z. Al‐Riyami
ECElizabeth Crowe
Elizabeth Crowe
TGthe ISBT COVID‐19 Working Group
the ISBT COVID‐19 Working Group
Growing evidence suggests that ABO blood group may play a role in the immunopathogenesis of SARS‐CoV‐2 infection, with group O individuals less likely to test positive and group A conferring a higher susceptibility to infection and propensity to severe disease. The level of evidence supporting an association between ABO type and SARS‐CoV‐2/COVID‐19 ranges from small observational studies, to genome‐wide‐association‐analyses and country‐level meta‐regression analyses. ABO blood group antigens are oligosaccharides expressed on red cells and other tissues (notably endothelium). There are several hypotheses to explain the differences in SARS‐CoV‐2 infection by ABO type. For example, anti‐A and/or anti‐B antibodies (e.g. present in group O individuals) could bind to corresponding antigens on the viral envelope and contribute to viral neutralization, thereby preventing target cell infection. The SARS‐CoV‐2 virus and SARS‐CoV spike (S) proteins may be bound by anti‐A isoagglutinins (e.g. present in group O and group B individuals), which may block interactions between virus and angiotensin‐converting‐enzyme‐2‐receptor, thereby preventing entry into lung epithelial cells. ABO type‐associated variations in angiotensin‐converting enzyme‐1 activity and levels of von Willebrand factor (VWF) and factor VIII could also influence adverse outcomes, notably in group A individuals who express high VWF levels. In conclusion, group O may be associated with a lower risk of SARS‐CoV‐2 infection and group A may be associated with a higher risk of SARS‐CoV‐2 infection along with severe disease. However, prospective and mechanistic studies are needed to verify several of the proposed associations. Based on the strength of available studies, there are insufficient data for guiding policy in this regard.

13 June 2020 in Vox Sanguinis
Verified
Journal Article
Open access
PDF file
EBEvan M. Bloch
Evan M. Bloch
RGRuchika Goel
Ruchika Goel
SWSilvano Wendel
Silvano Wendel
TBThierry Burnouf
Thierry Burnouf
AAArwa Z. Al‐Riyami
Arwa Z. Al‐Riyami
COCynthia So – Osman
Cynthia So – Osman
Background and objectives: COVID‐19 convalescent plasma (CCP) has been used, predominantly in high‐income countries (HICs) to treat COVID‐19; available data suggest the safety and efficacy of use. We sought to develop guidance for procurement and use of CCP, particularly in low‐ and middle‐income countries (LMICs) for which data are lacking.Materials and methods: A multidisciplinary, geographically representative group of individuals with expertise spanning transfusion medicine, infectious diseases and haematology was tasked with the development of a guidance document for CCP, drawing on expert opinion, survey of group members and review of available evidence. Three subgroups (i.e. donor, product and patient) were established based on self‐identified expertise and interest. Here, the donor and product‐related challenges are summarized and contrasted between HICs and LMICs with a view to guide related practices.Results: The challenges to advance CCP therapy are different between HICs and LMICs. Early challenges in HICs related to recruitment and qualification of sufficient donors to meet the growing demand. Antibody testing also posed a specific obstacle given lack of standardization, variable performance of the assays in use and uncertain interpretation of results. In LMICs, an extant transfusion deficit, suboptimal models of donor recruitment (e.g. reliance on replacement and paid donors), limited laboratory capacity for pre‐donation qualification and operational considerations could impede wide adoption.Conclusion: There has been wide‐scale adoption of CCP in many HICs, which could increase if clinical trials show efficacy of use. By contrast, LMICs, having received little attention, require locally applicable strategies for adoption of CCP.

8 March 2022 in Vox Sanguinis
Verified
Journal Article
Closed access
AAArwa Z. Al‐Riyami
Arwa Z. Al‐Riyami
TBThierry Burnouf
Thierry Burnouf
EWErica M. Wood
Erica M. Wood
DDDana V. Devine
Dana V. Devine
AOAdaeze Oreh
Adaeze Oreh
TGthe ISBT COVID‐19 Convalescent Plasma Working Group
the ISBT COVID‐19 Convalescent Plasma Working Group

8 July 2020 in ISBT Science Series
Verified
Journal Article
Closed access
PDF file
GPGopal Kumar Patidar
Gopal Kumar Patidar
YDYashaswi Dhiman
Yashaswi Dhiman

1 October 2013 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
GPGopal Kumar Patidar
Gopal Kumar Patidar
RSRatti Ram Sharma
Ratti Ram Sharma
NMNeelam Marwaha
Neelam Marwaha

24 September 2014 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Closed access
PDF file
SSSuchet Sachdev
Suchet Sachdev
KMKshitija Mittal
Kshitija Mittal
GPGopal Kumar Patidar
Gopal Kumar Patidar
NMNeelam Marwaha
Neelam Marwaha
RSRatti Ram Sharma
Ratti Ram Sharma
SASunil Kumar Arora
Sunil Kumar Arora